ES2616961T3 - Composición de anticuerpos pan-HER - Google Patents
Composición de anticuerpos pan-HER Download PDFInfo
- Publication number
- ES2616961T3 ES2616961T3 ES11797354.5T ES11797354T ES2616961T3 ES 2616961 T3 ES2616961 T3 ES 2616961T3 ES 11797354 T ES11797354 T ES 11797354T ES 2616961 T3 ES2616961 T3 ES 2616961T3
- Authority
- ES
- Spain
- Prior art keywords
- antibody
- cdr1
- seq
- amino acid
- acid sequences
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title abstract description 8
- 150000001413 amino acids Chemical class 0.000 abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 11
- 239000000427 antigen Substances 0.000 description 23
- 102000036639 antigens Human genes 0.000 description 23
- 108091007433 antigens Proteins 0.000 description 23
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 8
- 230000000890 antigenic effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 4
- 108060003951 Immunoglobulin Proteins 0.000 description 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 4
- 102100029986 Receptor tyrosine-protein kinase erbB-3 Human genes 0.000 description 4
- 101710100969 Receptor tyrosine-protein kinase erbB-3 Proteins 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 102000018358 immunoglobulin Human genes 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 101000851181 Homo sapiens Epidermal growth factor receptor Proteins 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 1
- 102100029981 Receptor tyrosine-protein kinase erbB-4 Human genes 0.000 description 1
- 101710100963 Receptor tyrosine-protein kinase erbB-4 Proteins 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091008874 T cell receptors Proteins 0.000 description 1
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 230000009422 growth inhibiting effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000013415 human tumor xenograft model Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US40878210P | 2010-11-01 | 2010-11-01 | |
| US408782P | 2010-11-01 | ||
| DK201000988 | 2010-11-01 | ||
| DKPA201000988 | 2010-11-01 | ||
| DK201100672 | 2011-09-05 | ||
| DKPA201100672 | 2011-09-05 | ||
| US201161531407P | 2011-09-06 | 2011-09-06 | |
| US201161531407P | 2011-09-06 | ||
| PCT/IB2011/054834 WO2012059857A2 (en) | 2010-11-01 | 2011-10-31 | Pan-her antibody composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2616961T3 true ES2616961T3 (es) | 2017-06-14 |
Family
ID=59014867
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11797354.5T Active ES2616961T3 (es) | 2010-11-01 | 2011-10-31 | Composición de anticuerpos pan-HER |
| ES11837656.5T Active ES2692379T3 (es) | 2010-11-01 | 2011-10-31 | Anticuerpos anti-HER3 y composiciones |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES11837656.5T Active ES2692379T3 (es) | 2010-11-01 | 2011-10-31 | Anticuerpos anti-HER3 y composiciones |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9217039B2 (enExample) |
| EP (3) | EP2635605B1 (enExample) |
| JP (2) | JP6186277B2 (enExample) |
| KR (2) | KR101862832B1 (enExample) |
| AU (2) | AU2011324871B2 (enExample) |
| CA (2) | CA2816519C (enExample) |
| DK (1) | DK2635604T3 (enExample) |
| ES (2) | ES2616961T3 (enExample) |
| IL (2) | IL225954B (enExample) |
| MX (2) | MX347981B (enExample) |
| PL (1) | PL2635604T3 (enExample) |
| TW (1) | TW201231066A (enExample) |
| WO (2) | WO2012059858A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2638579T3 (es) * | 2008-08-29 | 2017-10-23 | Symphogen A/S | Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico |
| WO2010029534A1 (en) | 2008-09-15 | 2010-03-18 | Yeda Research And Development Co. Ltd. | Antibody combinations and use of same for treating cancer |
| MA33892B1 (fr) | 2009-12-22 | 2013-01-02 | Roche Glycart Ag | Anticorps anti-her3, et leurs utilisations |
| US9155802B2 (en) | 2010-11-01 | 2015-10-13 | Symphogen A/S | Pan-HER antibody composition |
| MX347981B (es) | 2010-11-01 | 2017-05-22 | Symphogen As | Composicion de anticuerpos pan-her. |
| JP2014509593A (ja) * | 2011-03-15 | 2014-04-21 | メリマック ファーマシューティカルズ インコーポレーティッド | ＥｒｂＢ経路阻害剤に対する耐性の克服 |
| US9040047B2 (en) | 2011-05-16 | 2015-05-26 | Yeda Research And Development Co. Ltd. | Combinations of anti ErbB antibodies for the treatment of cancer |
| CA2952347A1 (en) * | 2011-07-01 | 2013-01-10 | Amgen Inc. | Mammalian cell culture |
| JP6180425B2 (ja) | 2011-11-23 | 2017-08-23 | メディミューン，エルエルシー | Ｈｅｒ３に特異的な結合分子及びそれらの使用 |
| CA2865082A1 (en) * | 2012-03-27 | 2013-10-03 | Genentech, Inc. | Diagnosis and treatments relating to her3 inhibitors |
| EP2844675B1 (en) | 2012-05-02 | 2019-01-02 | Symphogen A/S | Humanized pan-her antibody compositions |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| EA036902B1 (ru) * | 2013-09-20 | 2021-01-13 | Бристол-Майерс Сквибб Компани | Комбинирование anti-lag-3-антител и анти-pd-1-антител для лечения опухолей |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| US10745490B2 (en) | 2014-04-11 | 2020-08-18 | Celldex Therapeutics, Inc. | Anti-ErbB antibodies and methods of use thereof |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| AU2015313811A1 (en) | 2014-09-08 | 2017-04-06 | Yeda Research And Development Co. Ltd. | Compositions and methods for treating cancer resistant to a tyrosine kinase inhibitor (TKI) |
| CA2959716A1 (en) | 2014-09-08 | 2016-03-17 | Yeda Research And Development Co. Ltd. | Anti-her3 antibodies and uses of same |
| CA2961323C (en) | 2014-09-16 | 2021-11-30 | Symphogen A/S | Anti-met antibodies and compositions |
| EP3176183A1 (en) | 2015-12-02 | 2017-06-07 | Yeda Research and Development Co. Ltd | Compositions and methods for treating cancer not resistant to a tyrosine kinase inhibitor (tki) |
| MA43416A (fr) | 2015-12-11 | 2018-10-17 | Regeneron Pharma | Méthodes pour ralentir ou empêcher la croissance de tumeurs résistantes au blocage de l'egfr et/ou d'erbb3 |
| EP3397276A4 (en) | 2015-12-30 | 2019-12-18 | Kodiak Sciences Inc. | ANTIBODIES AND CONJUGATES THEREOF |
| US20190151346A1 (en) | 2016-05-10 | 2019-05-23 | INSERM (Institute National de la Santé et de la Recherche Médicale) | Combinations therapies for the treatment of cancer |
| MA49042A (fr) | 2017-04-05 | 2020-02-12 | Symphogen As | Polythérapies ciblant pd-1, tim-3 et lag-3 |
| EP3630179A2 (en) | 2017-05-30 | 2020-04-08 | Bristol-Myers Squibb Company | Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody |
| PT3631454T (pt) | 2017-05-30 | 2023-11-23 | Bristol Myers Squibb Co | Tratamento de tumores positivos para lag-3 |
| US12071476B2 (en) | 2018-03-02 | 2024-08-27 | Kodiak Sciences Inc. | IL-6 antibodies and fusion constructs and conjugates thereof |
| KR102846109B1 (ko) | 2018-09-07 | 2025-08-18 | 화이자 인코포레이티드 | 항-αvβ8 항체 및 그의 조성물 및 용도 |
| JP2022520649A (ja) * | 2019-02-14 | 2022-03-31 | メルス ナムローゼ フェンノートシャップ | Ｅｇｆｒ、ｈｅｒ２及びｈｅｒ３に結合する結合部分の組み合わせ |
| CN114426578B (zh) * | 2019-02-14 | 2025-03-21 | 美勒斯公司 | 结合egfr、her2及her3的结合部分的组合 |
| US20220259290A1 (en) * | 2019-07-24 | 2022-08-18 | Japan Science And Technology Agency | Innovative production technique for antibody-enzyme |
| AU2020364071A1 (en) | 2019-10-10 | 2022-05-26 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2022144836A1 (en) | 2020-12-31 | 2022-07-07 | Sanofi | Multifunctional natural killer (nk) cell engagers binding to nkp46 and cd123 |
| AU2023274452A1 (en) | 2022-05-27 | 2025-01-16 | Innate Pharma | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| AR132710A1 (es) | 2023-05-19 | 2025-07-23 | Servier Lab | Anticuerpos anti-met, adc, composiciones y usos de los mismos |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ331360A (en) | 1996-03-27 | 2000-03-27 | Genentech Inc | an antibody which binds to a ErbB3 protein and reduces heregulin-induced formation of a ErbB2-ErbB3 protein complex |
| US5968511A (en) * | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| AUPQ105799A0 (en) * | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| JP2003531588A (ja) * | 2000-04-11 | 2003-10-28 | ジェネンテック・インコーポレーテッド | 多価抗体とその用途 |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| SI1583830T1 (sl) | 2003-01-07 | 2006-12-31 | Symphogen As | Postopek za pripravo rekombinantnih poliklonskih proteinov |
| JPWO2004087763A1 (ja) * | 2003-03-31 | 2006-07-27 | 中外製薬株式会社 | Ｃｄ２２に対する改変抗体およびその利用 |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| BRPI0513714A (pt) | 2004-07-20 | 2008-05-13 | Symphogen As | procedimento para caracterização estrutural de uma proteìna policlonal recombinante ou uma linhagem de célula policlonal |
| KR20150140417A (ko) | 2004-07-22 | 2015-12-15 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| BRPI0518086A (pt) | 2004-12-07 | 2008-10-28 | Genentech Inc | métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| WO2008031531A1 (en) * | 2006-09-15 | 2008-03-20 | F. Hoffmann-La Roche Ag | Tumor therapy with a combination of anti-her2 antibodies |
| CA2678181C (en) * | 2007-02-16 | 2016-12-13 | Merrimack Pharmaceuticals, Inc. | Antibodies against erbb3 and uses thereof |
| ES2582386T3 (es) * | 2007-03-01 | 2016-09-12 | Symphogen A/S | Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico |
| DE602008002593D1 (de) | 2007-05-25 | 2010-10-28 | Symphogen As | Verfahren zur herstellung eines rekombinanten polyklonalen proteins |
| WO2009065414A1 (en) | 2007-11-22 | 2009-05-28 | Symphogen A/S | A method for characterization of a recombinant polyclonal protein |
| KR20110016899A (ko) | 2008-04-23 | 2011-02-18 | 심포젠 에이/에스 | 폴리클로날 단백질을 제조하는 방법 |
| BRPI0917871A2 (pt) | 2008-08-15 | 2017-06-20 | Merrimack Pharmaceuticals Inc | agente terapêutico anti-erbb3 para uso em terapia de um tumor, métodos para predizer responsividade de um tumor de um agente terapêutco anti-erbb3, para selecionar terapia anti-erbb3 para um paciente, para predizer a resposta de células ao tratamento com um agente terapêutico, para identificar um biomarcador, e para evitar administração de uma droga para câncer anti-erbb3, e, kit para predizer a resposta das células ao tratamento com um agente terapêutico |
| ES2638579T3 (es) * | 2008-08-29 | 2017-10-23 | Symphogen A/S | Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico |
| EP2335068A4 (en) | 2008-10-06 | 2012-07-25 | Symphogen As | METHOD FOR IDENTIFYING AND SELECTING CANDIDATES MEDICINES FOR COMBINATORIAL DRUG PRODUCTS |
| MA33198B1 (fr) * | 2009-03-20 | 2012-04-02 | Genentech Inc | Anticorps anti-her di-spécifiques |
| PE20120550A1 (es) | 2009-04-07 | 2012-05-21 | Roche Glycart Ag | ANTICUERPOS BIESPECIFICOS ANTI-ErbB-3/ANTI-C-MET |
| US20100256340A1 (en) | 2009-04-07 | 2010-10-07 | Ulrich Brinkmann | Trivalent, bispecific antibodies |
| US8362215B2 (en) | 2009-04-29 | 2013-01-29 | Trellis Bioscience, Llc | Antibodies immunoreactive with heregulin-coupled HER3 |
| CA2766608C (en) * | 2009-07-06 | 2018-06-19 | F. Hoffmann-La Roche Ag | Bi-specific digoxigenin binding antibodies |
| CN103002912A (zh) * | 2009-08-21 | 2013-03-27 | 梅里麦克制药股份有限公司 | 针对ErbB3的胞外结构域的抗体及其用途 |
| US20120195831A1 (en) | 2009-10-09 | 2012-08-02 | Ningyan Zhang | Generation, characterization and uses thereof of anti-her3 antibodies |
| AU2010319483B2 (en) | 2009-11-13 | 2015-03-12 | Amgen Inc. | Material and methods for treating or preventing HER-3 associated diseases |
| TW201141519A (en) | 2010-03-04 | 2011-12-01 | Symphogen As | Anti-HER2 antibodies and compositions |
| RU2568051C2 (ru) | 2010-04-09 | 2015-11-10 | Авео Фармасьютикалз, Инк. | АНТИТЕЛА К ErbB3 |
| ES2620255T3 (es) | 2010-08-20 | 2017-06-28 | Novartis Ag | Anticuerpos para el receptor del factor de crecimiento epidérmico 3 (HER3) |
| MX347981B (es) | 2010-11-01 | 2017-05-22 | Symphogen As | Composicion de anticuerpos pan-her. |
-
2011
- 2011-10-31 MX MX2013004899A patent/MX347981B/es active IP Right Grant
- 2011-10-31 AU AU2011324871A patent/AU2011324871B2/en not_active Ceased
- 2011-10-31 EP EP11837656.5A patent/EP2635605B1/en not_active Not-in-force
- 2011-10-31 EP EP16200853.6A patent/EP3156421B1/en not_active Not-in-force
- 2011-10-31 WO PCT/IB2011/054835 patent/WO2012059858A1/en not_active Ceased
- 2011-10-31 US US13/882,807 patent/US9217039B2/en not_active Expired - Fee Related
- 2011-10-31 MX MX2013004897A patent/MX348637B/es active IP Right Grant
- 2011-10-31 DK DK11797354.5T patent/DK2635604T3/en active
- 2011-10-31 KR KR1020137013561A patent/KR101862832B1/ko not_active Expired - Fee Related
- 2011-10-31 CA CA2816519A patent/CA2816519C/en not_active Expired - Fee Related
- 2011-10-31 EP EP11797354.5A patent/EP2635604B1/en not_active Not-in-force
- 2011-10-31 ES ES11797354.5T patent/ES2616961T3/es active Active
- 2011-10-31 ES ES11837656.5T patent/ES2692379T3/es active Active
- 2011-10-31 JP JP2013535578A patent/JP6186277B2/ja not_active Expired - Fee Related
- 2011-10-31 KR KR1020137013552A patent/KR101773120B1/ko not_active Expired - Fee Related
- 2011-10-31 AU AU2011324870A patent/AU2011324870B2/en not_active Ceased
- 2011-10-31 PL PL11797354T patent/PL2635604T3/pl unknown
- 2011-10-31 JP JP2013535577A patent/JP6033783B2/ja not_active Expired - Fee Related
- 2011-10-31 WO PCT/IB2011/054834 patent/WO2012059857A2/en not_active Ceased
- 2011-10-31 CA CA2816520A patent/CA2816520C/en not_active Expired - Fee Related
- 2011-11-01 TW TW100139897A patent/TW201231066A/zh unknown
-
2013
- 2013-04-25 IL IL225954A patent/IL225954B/en active IP Right Grant
- 2013-04-25 IL IL225953A patent/IL225953A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2616961T3 (es) | Composición de anticuerpos pan-HER | |
| US20230059353A1 (en) | Antibodies directed to her-3 and uses thereof | |
| RU2018137110A (ru) | Антитела против psma и их применение | |
| TWI741987B (zh) | 特異性針對過度磷酸化τ蛋白之抗體及其使用方法 | |
| ES2582386T3 (es) | Composiciones de anticuerpos recombinantes contra el receptor del factor de crecimiento epidérmico | |
| ES2686335T3 (es) | Nuevos anticuerpos que inhiben la dimerización de c-Met y sus utilizaciones | |
| ES2610474T3 (es) | Diagnóstico y tratamiento de la enfermedad de Alzheimer y otras enfermedades neurodegenerativas causantes de demencia | |
| US20140212423A1 (en) | Blood-brain barrier penetrating dual specific binding proteins | |
| JP2020522261A5 (enExample) | ||
| WO2016191246A3 (en) | T cell receptor-like antibodies specific for a prame peptide | |
| JP2020536504A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| PE20061152A1 (es) | Anticuerpos humanizados que reconocen el peptido beta amiloideo | |
| AR052051A1 (es) | Anticuerpos ab humanizados usados en mejorar la cognicion | |
| RU2011148918A (ru) | Иммуноглобулин с двумя вариабельными доменами и его применение | |
| ME02678B (me) | Antitijela na ox-40 i postupci njihove primjene | |
| HRP20181087T1 (hr) | Pripravak i postupak dijagnostike i liječenja bolesti povezanih s degeneracijom neurita | |
| JP2019523651A5 (enExample) | ||
| RU2019121086A (ru) | Иммунотерапия с применением антител, связывающих лиганд 1 белка программируемой смерти клеток (PD-L1) | |
| HRP20220405T1 (hr) | Protutijela protiv ngf i njihova upotreba | |
| EA201491851A1 (ru) | Композиции и способы для лечения болезни альцгеймера | |
| RU2021111382A (ru) | Мультивалентные и мультиспецифические гибридные белки, связывающиеся с dr5 | |
| JP2017532005A5 (enExample) | ||
| US20220073598A1 (en) | Antagonists | |
| RU2016141285A (ru) | Биспецифические антигенсвязывающие полипептиды |